Study of Tesetaxel in Japanese Patients With Solid Tumors
Status:
Unknown status
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Tesetaxel is an orally active tubulin-binding inhibitor of the taxane class. Evaluation of
tesetaxel in Japanese patients has been limited. This study is being conducted to determine
the maximum tolerated dose and safety of tesetaxel administered orally once every 21 days to
Japanese patients.